Latest Innovation News

Titomic Limited has landed a $1.7 million Early Manufacturing Development contract with a leading defense prime, aiming to fast-track production of advanced defense components using its proprietary cold spray additive manufacturing technology.

Alexium International has acquired Microtek Laboratories’ microencapsulation and phase-change material business, backed by a $6.8 million entitlement offer to strengthen its manufacturing and innovation capabilities in the US.

4DMedical has gained Canadian regulatory approval for its innovative CT – VQ™ ventilation-perfusion imaging technology, enabling immediate commercial rollout through Philips and expanding its North American footprint.

Radiopharm Theranostics reports promising interim Phase 2b results for RAD 101, achieving 92% concordance with MRI in detecting brain metastases, paving the way for a pivotal study in 2026.

Cann Group Limited has successfully completed a significant debt restructure and equity raising, improving its financial footing and liquidity to support future growth.

Neuren Pharmaceuticals’ partner Acadia secures FDA approval for DAYBUE STIX, a new powder formulation of trofinetide offering greater flexibility for Rett syndrome patients. This milestone expands treatment options and sets the stage for increased royalty revenue in 2026.

Fortifai Limited has acquired an exclusive license to Nol8, a breakthrough real-time data processing technology developed by the Technion. This acquisition positions Fortifai to revolutionize data handling across gaming, AI, finance, and cybersecurity sectors.

Loyal Metals has intersected 60 metres of rich chalcocite copper mineralisation near the surface at its Highway Reward Project, confirming the presence of extensive copper-gold deposits and advancing exploration efforts with a third drill underway.

Rio Tinto has completed due diligence on Calix’s Zesty Green Iron Demonstration Project, unlocking an initial $3 million investment and moving the venture closer to commercial reality.

Imricor Medical Systems has secured Institutional Review Board approval for the University of Virginia Health to join its VISABL-AFL clinical trial, marking a key expansion in the US. Procedures are set to begin early next year, supporting Imricor’s progress toward FDA approval and commercialisation.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Proteomics International's PromarkerD blood test shows clinically meaningful accuracy in predicting diabetic kidney disease among Aboriginal Australians, matching performance in non-Indigenous populations. This advancement offers a promising tool for early intervention in a high-risk group.